{"organizations": [], "uuid": "ed014c5fd4e6117b6eb390667262fb3005606cf3", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-ohr-pharmaceutical-announces-effic/brief-ohr-pharmaceutical-announces-efficacy-results-from-the-mako-study-in-wet-amd-idUSFWN1P00FM", "country": "US", "domain_rank": 408, "title": "BRIEF-Ohr Pharmaceutical Announces Efficacy Results From The Mako Study In Wet-Amd", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-05T13:07:00.000+02:00", "replies_count": 0, "uuid": "ed014c5fd4e6117b6eb390667262fb3005606cf3"}, "author": "", "url": "https://www.reuters.com/article/brief-ohr-pharmaceutical-announces-effic/brief-ohr-pharmaceutical-announces-efficacy-results-from-the-mako-study-in-wet-amd-idUSFWN1P00FM", "ord_in_thread": 0, "title": "BRIEF-Ohr Pharmaceutical Announces Efficacy Results From The Mako Study In Wet-Amd", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "ohr pharmaceutical inc", "sentiment": "none"}, {"name": "ohr pharmaceutical inc", "sentiment": "none"}, {"name": "amd reuters", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 08 AM / in 5 minutes BRIEF-Ohr Pharmaceutical Announces Efficacy Results From The Mako Study In Wet-Amd Reuters Staff \nJan 5 (Reuters) - Ohr Pharmaceutical Inc: \n* OHR PHARMACEUTICAL ANNOUNCES EFFICACY RESULTS FROM THE MAKO STUDY IN WET-AMD \n* OHR PHARMACEUTICAL INC - ‍TOPLINE DATA FROM MAKO STUDY DID NOT MEET ITS PRIMARY EFFICACY ENDPOINT​ \n* OHR PHARMACEUTICAL INC - “WE ARE VERY DISAPPOINTED WITH OUTCOME OF MAKO STUDY” \n* OHR PHARMACEUTICAL INC - ‍INTEND TO EVALUATE STRATEGIC ALTERNATIVES TO “MAXIMIZE SHAREHOLDER VALUE”​ \n* OHR PHARMA - SUBJECTS RECEIVING SQUALAMINE COMBINATION THERAPY ACHIEVED MEAN GAIN OF 8.33 LETTERS FROM BASELINE VERSUS 10.58 FROM LUCENTIS MONOTHERAPY Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-01-05T13:07:00.000+02:00", "crawled": "2018-01-05T13:20:43.006+02:00", "highlightTitle": ""}